Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0002 0.00 (0.00%)
As of 08/3/2026
Compare

EFTR vs. CMRA, SYRS, ADTX, CALA, and SMFL

Should you buy eFFECTOR Therapeutics stock or one of its competitors? MarketBeat compares eFFECTOR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eFFECTOR Therapeutics include Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), Aditxt (ADTX), Calithera Biosciences (CALA), and Smart for Life (SMFL). These companies are all part of the "pharmaceuticals" industry.

How does eFFECTOR Therapeutics compare to Comera Life Sciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

eFFECTOR Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Comera Life Sciences beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

eFFECTOR Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
eFFECTOR Therapeutics N/A N/A N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

eFFECTOR Therapeutics has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
eFFECTOR Therapeutics Neutral

Summary

eFFECTOR Therapeutics beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Aditxt?

Aditxt (NASDAQ:ADTX) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

eFFECTOR Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. eFFECTOR Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
eFFECTOR Therapeutics N/A N/A N/A

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aditxt has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

eFFECTOR Therapeutics has lower revenue, but higher earnings than Aditxt. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.16-$41.71M-$100.79 thousandN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Aditxt's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Aditxt Neutral
eFFECTOR Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

eFFECTOR Therapeutics beats Aditxt on 8 of the 11 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
eFFECTOR Therapeutics Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Calithera Biosciences has a beta of -1.36, indicating that its stock price is 236% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 5 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Smart for Life has a beta of 15.05, suggesting that its stock price is 1,405% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
eFFECTOR Therapeutics Neutral

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$11.46B$6.80B$13.01B
Dividend YieldN/A2.74%2.60%10.03%
P/E Ratio0.00791.61279.7225.54
Price / SalesN/A947.20648.16115.94
Price / CashN/A14.8228.6434.82
Price / Book0.0010.4411.126.36
Net Income-$35.81M$2.81B$3.48B$347.58M
7 Day PerformanceN/A1.83%2.59%3.17%
1 Month PerformanceN/A-3.14%-2.79%-2.06%
1 Year PerformanceN/A154.81%64.29%21.19%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+0.0%$1KN/AN/A10
CMRA
Comera Life Sciences
N/A$0.00
+∞		N/AN/A$3K$1.00MN/A2
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-75.0%$3K$386KN/A120
ADTX
Aditxt
0.0752 of 5 stars		$0.00
flat		N/A-100.0%$2K$14.34KN/A60
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
AI billionaires want YOUR electricity
More than 200 utilities, developers and states have joined a voluntary pledge to keep Big Tech's AI power cost...
Monument Traders Alliance | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...
Chaikin Analytics | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
This loan shouldn't be possible
On May 21, 2026, a federal board unanimously approved a roughly 3 billion dollar loan to a single American min...
Behind the Markets | Sponsoredtc pixel